Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113641 | 1.00 | NOS2 (0.55) | NOS2GRIN2BGRIN1CES1GRIN2D | |
| SCHEMBL8355436 | 1.00 | NOS2 (0.55) | NOS2GRIN2BGRIN1CES1GRIN2D | |
| SCHEMBL18343605 | 0.85 | NOS2 (0.52) | NOS2GRIN2BGRIN1CES1GRIN2D | |
| SCHEMBL18343608 | 0.85 | NOS2 (0.52) | NOS2GRIN2BGRIN1CES1GRIN2D | |
| SCHEMBL29870896 | 0.81 | GRIN1 (0.49) | GRIN2BGRIN1CES1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2383484 | 0.78 | GRIN2B (0.55) | GRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL2371436 | 0.78 | GRIN2B (0.55) | GRIN2BALDH1A1SMN1; SMN2 | |
| SCHEMBL22068857 | 0.76 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL22068858 | 0.76 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL104888 | 0.76 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448939-B1 | 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2448939-B1 | 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-8828997-B2 | 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-8828997-B2 | 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-8828997-B2 | 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20120142679-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142679-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142679-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| EP-2448939-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001112-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001112-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-1044959-B1 | Process for preparing a 1,1,1-trifluoro-2-aminoalkane | BASF AG (DE) | 2002-12-04 | — | — | EP | disclosed |
| US-6166259-A | Process for preparing a 1,1,1-trifluoro-2-aminoalkane | AMERICAN CYANAMID COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1044959-A2 | Process for preparing a 1,1,1-trifluoro-2-aminoalkane | American Cyanamid Company (US) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142679-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | LPXN, LBR, HCLS1 | NOS2 2365/4885GRIN2B 2250/4885GRIN1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.